Healthcare / BiotechnologyHKSE
$5.78
-0.21 (-3.51%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $88.8M · quality 48.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
53/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.2B
P/E
8.9x
↓EV/EBITDA
5.8x
↓ROE
8.4%
↑Gross Margin
80.7%
↑Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.1%
FCF CAGR
—
FCF margin
11.5%
FCF / Net income
1.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.31B · net income $138.4M · FCF $150.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.31B | $1.31B | $1.37B | $1.29B | $1.13B |
| Net Income | $138.4M | $138.4M | $138.6M | $119.8M | $59.9M |
| EBITDA | $211.8M | $211.8M | $212.7M | $180.5M | $96.2M |
| EPS | — | — | 0.68 | 0.49 | 0.24 |
| Gross Margin | 80.7% | 80.7% | 79.0% | 77.0% | 75.9% |
| Operating Margin | 12.2% | 12.2% | 13.2% | 11.3% | 5.4% |
| Net Margin | 10.6% | 10.6% | 10.1% | 9.3% | 5.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.08 | 0.19 | 0.29 |
| Current Ratio | 4.46 | 4.46 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $150.2M | $150.2M | $14.9M | $88.8M | $-36.4M |
| Returns | |||||
| ROE | 8.4% | 8.4% | 9.1% | 13.3% | 7.8% |
| Valuation | |||||
| P/E | 8.89 | 8.89 | 9.15 | — | — |
| EV/EBITDA | 5.81 | 5.81 | 4.01 | — | — |
| P/B | 0.86 | 0.86 | 0.84 | — | — |
| Growth & Yield | |||||
| Revenue Growth | -4.6% | -4.6% | 6.4% | 14.4% | — |
| EPS Growth | — | — | 39.3% | 100.1% | — |
| Dividend Yield | 1.1% | 1.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-2.9%
Start / end P/E
n/dx → n/dx
EPS bridge
0.68 → n/d
Residual
-4.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.